Lineage Cell Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2012 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2012 to Q4 2024.
  • Lineage Cell Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending December 31, 2024 was $1.32M, a 24.1% increase year-over-year.
  • Lineage Cell Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending December 31, 2024 was $5.08M, a 9.42% increase year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $5.08M, a 9.42% increase from 2023.
  • Lineage Cell Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $4.64M, a 8.23% increase from 2022.
  • Lineage Cell Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4.29M.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $5.08M $1.32M +$255K +24.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-10
Q3 2024 $4.82M $1.33M +$61K +4.81% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $4.76M $1.27M -$11K -0.86% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $4.77M $1.16M +$132K +12.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $4.64M $1.06M Oct 1, 2023 Dec 31, 2023 10-K 2025-03-10
Q3 2023 $1.27M Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $1.28M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $1.03M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q3 2018 $123K -$850K -87.4% Jul 1, 2018 Sep 30, 2018 10-Q 2018-11-08
Q1 2018 $984K -$42K -4.09% Jan 1, 2018 Mar 31, 2018 10-Q 2018-05-10
Q3 2017 $4.55M $973K +$263K +37% Jul 1, 2017 Sep 30, 2017 10-Q 2017-11-09
Q2 2017 $4.29M $905K -$1.32M -59.2% Apr 1, 2017 Jun 30, 2017 10-Q 2017-08-09
Q1 2017 $5.6M $1.03M -$2.35M -69.6% Jan 1, 2017 Mar 31, 2017 10-Q 2017-05-10
Q4 2016 $7.95M $1.65M Oct 1, 2016 Dec 31, 2016 10-K 2017-03-16
Q3 2016 $710K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $2.22M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $3.37M +$1.46M +76.2% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-10
Q1 2015 $1.91M +$1.11M +139% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q1 2014 $802K +$110K +15.8% Jan 1, 2014 Mar 31, 2014 10-Q 2014-05-12
Q1 2013 $692K +$219K +46.2% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
Q1 2012 $473K Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.